Skip to content

新闻稿

大乐透玩法中奖规则:Illumina Names Dr. Phil Febbo Chief Medical Officer

超级大乐透中奖规则 www.slf2t.cn

Brings unmatched bench-to-bedside expertise to catalyze the adoption of precision medicine

SAN DIEGO--(BUSINESS WIRE)--Mar. 12, 2018-- Illumina, Inc.?(NASDAQ:ILMN) announced?today the appointment of Dr. Phil Febbo, a leading physician scientist, as Chief Medical Officer (CMO), starting March 26, 2018. In his new role, Dr. Febbo will be responsible for developing and executing on the Company’s medical strategy to drive genomic testing into healthcare practice.

This press release features multimedia. View the full release here://www.businesswire.com/news/home/20180312006000/en/

Illumina names Dr. Phil Febbo Chief Medical Officer - Brings unmatched bench-to-bedside expertise to ...

Illumina names Dr. Phil Febbo Chief Medical Officer - Brings unmatched bench-to-bedside expertise to catalyze the adoption of precision medicine. (Photo: Business Wire)

“We are very excited to welcome Dr. Febbo, who comes to us at a transformative time in the evolution of genomic medicine,” said Garret Hampton, Ph.D., Executive Vice President of Clinical Genomics at Illumina. “Phil brings a wealth of clinical and scientific experience to Illumina, from understanding the genomic basis of common human cancers, to the development of clinical tests based on next generation sequencing. We believe that his experience will ensure that Illumina is uniquely positioned to change medical practice with the use of genomics.”

For the past 25 years, Dr. Febbo has worked at leading institutions throughout the United States, most recently serving as CMO of Genomic Health (NASDAQ:GHDX). Prior to joining Genomic Health, Dr. Febbo served as Professor of Medicine and Urology at the University of California, San Francisco (UCSF), where his laboratory focused on using genomics to understand the biology and clinical behavior of prostate cancer, and his clinical practice focused on genitourinary oncology. While at UCSF, Dr. Febbo was the co-leader of the Prostate Cancer Program at the Helen Diller Family Comprehensive Cancer Center and the Program Principal Investigator of the Translational Research Program for the Alliance for Clinical Trials in Oncology.

Dr. Febbo holds a Bachelor of Arts degree in Biology from Dartmouth College, received his M.D. degree at UCSF, and completed his internal medicine residency at the Brigham and Women’s Hospital. After his fellowship in medical oncology at the Dana-Farber Cancer Institute, he was an Attending Physician in the Genitourinary Oncology Center at Dana-Farber, Instructor at Harvard Medical School, and a post-doctoral fellow in Dr. Todd Golub's laboratory at Dana-Farber, as well as the Whitehead Institute Center for Genomic Research of MIT (now the Broad Institute). In 2004, Dr. Febbo moved to Duke University Medical Center’s Institute of Genome Sciences and Policy. He has been a member of the American Society for Clinical Investigation since 2009.

About Illumina

Illumina?is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets.?Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit?www.illumina.com?and follow @illumina.

Use of forward-looking statements

This release contains forward-looking statements that involve risks and uncertainties. These forward-looking statements are based on our expectations as of the date of this release and may differ materially from actual future events or results. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are (i) our ability to further develop and commercialize our instruments and consumables, and to deploy new products, services and applications, and expand the markets for our technology platforms; (ii) our ability to manufacture robust instrumentation and consumables; (iii) our ability to successfully identify and integrate acquired technologies, products or businesses; (iv) the future conduct and growth of the business and the markets in which we operate; and (v) challenges inherent in developing, manufacturing, and launching new products and services, together with other factors detailed in our filings with the?Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts’ expectations, or to provide interim reports or updates on the progress of the current quarter.

Source: Illumina, Inc.

Illumina, Inc.
Investors:
Jacquie Ross, CFA
858-882-2172
[email protected]
or
Media:
Lisa Warshaw
323-360-8778
[email protected]

Recent Articles

Alt text for article
Veterans Helping Veterans Conquer the 'Invisible Wound'
Alt text for article
Illumina Partners with Blue Cross Blue Shield Association
Alt text for article
Oncology: Restoring Order from Disorder
  • 骆惠宁主持召开十一届省委全面深化改革领导小组第十五次会议 2018-11-13
  • 我国首部军民融合专业期刊创刊发行 2018-10-08
  • 中国跳水:“梦之队”有望包揽里约奥运8金 2018-08-17
  • 把党的领导贯穿军事科研工作各方面和全过程 2018-08-13
  • 回复@老老保老张工:像铁环到一边去!咱真的没兴趣理你这种搞不清局部和整体是啥关系的老蚕。 2018-08-12
  • 回复@大雨582:社会人不可能像自然人一样自由,你还得尊重别人的意愿!不然咱随便生产啥都强行让你要,咱是自由了,你呢? 2018-08-12
  • 95后社交保鲜期:朋友圈士别三日当刮目相看 2018-08-11
  • 高清:世界杯小组赛B组摩洛哥对阵伊朗 两队球迷花样助阵 2018-08-11
  • 情浓端午——临汾建设社区15分钟便民服务志愿者在行动 2018-08-10
  • 第526期:北方春饼PK南方春卷,你更喜欢吃哪一种? 2018-08-09
  • 苗山脱贫影像志——父母在 不远行 2018-08-09
  • “巨无霸”蚊子刷新世界纪录 2018-08-08
  • 巢湖市烔炀大道等一批项目通过市规委会审议 2018-08-07
  • “创新从来都是九死一生” 2018-08-07
  • 浙大科研团队15载攻克歼20等飞机装配系列难题 2018-08-06
  • 964| 768| 257| 737| 908| 364| 930| 116| 223| 348|